Business Wire

Adrestia Appoints Human Genetics Leader, Professor John Perry, to Build Human Genetics Computational Platform

Share

Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced the appointment of Professor John R.B. Perry as its Vice President, Human Genetics. Dr Perry is a world-renowned expert in human population genetics at the University of Cambridge with a track record of identifying genetic drivers of complex, multigenic diseases and health-related traits. His expertise will complement Adrestia’s technology platform, which is already progressing a series of first-in-class therapies to treat both rare and common diseases with a genetic component.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005013/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Professor John R.B. Perry, Vice President, Human Genetics (Photo: Business Wire)

“We are on the cusp of a revolution in drug discovery” said Dr Perry. “Within the 8 billion living humans, each single base substitution in the genome that is compatible with life is likely to be present somewhere. Studying this genetic diversity in population studies gives us a hypothesis-free, genome wide screen for identifying and validating genes causing or influencing human disease. Due to advances in genome sequencing technologies and the advent of large-scale population studies, we can now phenotype human genetic knockouts at scale, leading to rapid validation of new drug discovery targets.” said Dr Perry. “I’m excited to apply these advanced techniques for maximum clinical impact. Combining population genetics with Adrestia’s synthetic rescue platform provides unprecedented opportunities to efficiently unlock new ways of treating some of the world’s most intractable diseases”.

Throughout his career and in recent years at the University of Cambridge, Professor Perry has been involved in discovering many of the first genetic drivers of diverse complex diseases including obesity, Type 2 diabetes, reproductive disorders and aspects of behavior. His work to better understand the genetic architecture of disease will enable more efficient drug target selection and the design of more predictive models of disease, both translating into higher drug development success rates. His career has been deeply embedded in the UK’s world-leading projects in population genomic analysis, including the UK Biobank, a ground-breaking resource containing in-depth genetic and health information from half a million participants. These projects have created deep expertise and an infrastructure that can be further leveraged for effective drug development at Adrestia.

Despite advances in genetic technologies, many genes known to directly cause disease remain undruggable. Synthetic rescue offers a fresh approach: rather than targeting the causative mutation, a synthetic rescue drug modulates the product of another, functionally connected gene, correcting the effects of the disease mutation and ‘rescuing’ cells from disease. The concept is underpinned by a deep understanding of genetic networks, and its therapeutic potential is illustrated in families where a member born with a disease-causing mutation is protected from disease due to a second ‘rescue’ mutation. Synthetic rescue presents new opportunities for drug development across all diseases that have a genetic component, including prevalent conditions.

“Traditional drug development is risky and expensive” said Robert Johnson, Chief Executive Officer of Adrestia. “We believe that our synthetic rescue platform, supplemented by John’s expertise in human genetics, offers a new paradigm, where the probability of success is markedly higher, the cost of development is dramatically lower and the time to clinical proof of concept is substantially shorter. We warmly welcome John to our team, which is united in a singular mission: to deliver revolutionary new medicines to patients suffering from devastating diseases”.

Dr Perry is Professor of Molecular Endocrinology at the University of Cambridge and Medical Research Council (MRC) Programme Leader and Investigator at the University’s Institute of Metabolic Science. He also serves as an Associate Group Leader at The Gurdon Institute at the University of Cambridge, as well as being a Fellow and Director of Studies at King’s College Cambridge. He will continue in these roles while serving at Adrestia.

Prior to joining the MRC Epidemiology Unit, Dr Perry was a Sir Henry Wellcome Fellow, holding visiting positions at the University of Exeter Medical School; the Wellcome Trust Centre for Human Genetics at the University of Oxford; the Department of Twin Research at Kings College London and the Center for Statistical Genetics at the University of Michigan. He has co-authored over 150 publications in peer reviewed journals, many in leading journals such as Nature, Science, Nature Genetics and Nature Medicine. Dr Perry completed his Ph.D. in Human Genetics at the University of Exeter, UK and before then had a background in computer science.

About Adrestia’s synthetic rescue platform

Adrestia has developed a leading synthetic rescue drug development platform, which has already identified completely new approaches to treating intractable genetic diseases. The platform includes multiple components, each designed to yield new insights into how every gene in the human genome modifies a particular disease’s cellular phenotype. These insights are married with human genetic datasets to provide robust validation of new druggable targets and build an ever-growing synthetic rescue ‘Atlas’ of the human genome. As the Atlas expands, the opportunities to use synthetic rescue drugs to treat both rare and common diseases continue to grow.

This scalable platform builds on decades of research by Professor Steve Jackson’s laboratory at the University of Cambridge into synthetic rescue and the related concept of synthetic lethality for the treatment of cancer. The Jackson Laboratory’s work has yielded a wealth of concepts, techniques, and know-how, now translated into Adrestia’s platform.

About Adrestia

Adrestia is a leader in synthetic rescue therapies for genetic diseases. As many directly causative mutations are not druggable, synthetic rescue embraces the much broader target set represented by functionally connected genes, to correct the effects of the causative mutations and ‘rescue’ health. Adrestia is creating a synthetic rescue ‘Atlas’ of the human genome and advancing a portfolio of first-in-class therapies, initially for neurologic, neuromuscular and cardiomyopathic diseases. Adrestia’s platform and in-house programs are complemented by a target discovery alliance with GSK and a Huntington’s disease collaboration with noted researchers including Dr Sarah Tabrizi at University College London.

Adrestia was co-founded by Professor Steve Jackson and the deep technology investment fund Ahren Innovation Capital, which co-led Adrestia’s Series A financing along with GSK. Jackson co-originated the first synthetic lethality drug, olaparib, which was the first drug approved to treat cancers caused by inherited mutations. For further information, please visit: http://www.adrestia.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investors
Robert Johnson
investors@adrestia.com

Media
Tom Donovan
tom@lyrebird.bio
+1 857 559 3397

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Verdane Partners with Climate Tech Leader Cleanwatts28.6.2022 17:00:00 CEST | Press release

Verdane, the European specialist growth equity investor, through its impact fund Idun, has invested in Cleanwatts, an energy software company on a mission to accelerate global energy decarbonization and alleviate energy poverty. Cleanwatts, which grew year-on-year revenues by 65% in 2021 and expects 2022 revenue growth of more than 200%, offers innovative energy management solutions that help local communities unlock the benefits of optimized renewable energy consumption, generation, storage, trading, and balancing. The partnership, in which Verdane is set to invest up to EUR25m, will draw on Verdane’s deep expertise of scaling SaaS companies, international network and in-house team of operating specialists. Cleanwatts is a Portuguese energy management software company that deploys renewable energy communities (RECs) in countries with advanced legal frameworks and policies that enable the activation of local energy markets. The company operates in Portugal (HQ), Italy, Spain, and the U

Andersen Global Enters New Zealand With the Addition of Two Collaborating Firms28.6.2022 15:30:00 CEST | Press release

Andersen Global establishes tax and legal capabilities in New Zealand through Collaboration Agreements with two Auckland-based firms – law firm Turner Hopkins, and tax and advisory firm Bellingham Wallace. The firms maintain deep connections in the region and will play a pivotal role in driving business and delivering integrated, global solutions to create long-term value for clients. Turner Hopkins was founded in 1923, and for nearly 100 years, has provided full-service capabilities in real estate, corporate and commercial law, litigation, finance, employment law, family, private client, estate and immigration. Turner Hopkins’ interdisciplinary team of professionals has vast experience working across a suite of industries and addressing client needs with comprehensive, customized solutions. “We pride ourselves on our client-focused approach and our commitment to ensuring that we retain the highest caliber of lawyers and professionals, which has allowed us to maintain a competitive edg

Synaptics Selects Allegro DVT’s VVC Compliance Streams28.6.2022 15:30:00 CEST | Press release

Allegro DVT, the leading provider of video codec compliance test suites and semiconductor video IPs, today announced that Synaptics Incorporated, one of the world's largest fabless semiconductor companies, has selected Allegro DVT’s VVC test streams to ensure full compliance of Synaptics’ products with the new emerging VVC video compression standard. Versatile Video Coding (VVC), also known as H.266, is the latest video compression standard that was finalized in 2020. It is the successor of HEVC/H.265 and was conceived to achieve two primary goals: improved compression performance and versatility to support a wide range of video applications such as mobile telephony, VOD, Broadcasting, OTT streaming, videoconferencing, screen content, 360° and scalable coding. Craig Stein, SVP and GM of Mobile and IoT at Synaptics, commented, “The depth and breadth of testing that Allegro’s VVC test suite solution provides ensures Synaptics’ VVC decoder implementation is robust and fully compliant with

TA Announces Advantive, a New Mission-Critical Software Provider for Specialty Manufacturing and Distribution Businesses28.6.2022 15:13:00 CEST | Press release

TA, a leading global growth private equity firm with more than four decades of enterprise software investing experience, in partnership with ST6, an elite team of software operating executives, has formed a global software provider called Advantive. The new company offers Enterprise Resource Planning (ERP), Manufacturing Execution Systems (MES), and Statistical Process Control (SPC) software solutions for specialty manufacturers and wholesale distributors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220628005803/en/ Advantive, which comes together through the combination of Advantzware, DDI System, Distribution One, InfinityQS, Kiwiplan and VIA, has more than 2,500 customers today across a number of industries including corrugated and packaging manufacturing, equipment and supply wholesale distributors, and automotive and other specialty manufacturers. Advantive will be headquartered in Tampa, Florida. Benoit de la Tour,

SonALAsense Achieves Significant Clinical, Growth and Funding Milestones Toward its Mission to Soundly Defeat Cancer28.6.2022 15:00:00 CEST | Press release

SonALAsense, a pioneer in the development of SONALA-001 and sonodynamic therapy (SDT), a new drug-device combination developed to manage deadly cancers so patients can become survivors, today announced clinical, organizational and growth updates. It is the only company with SDT in clinical trials. “At SonALAsense, we have been on a journey to develop a non-invasive treatment option for patients with rare brain cancers who often have little hope,” said Mark de Souza, PhD, Founder and Chief Executive Officer. “Today we are excited to announce the culmination of our hard work as we confidently advance SDT into clinical trials as the only non-invasive drug-device combination therapy for the treatment of recurrent glioblastoma multiforme (rGBM) and diffuse intrinsic pontine glioma (DIPG).” Clinical Update SonALAsense is working on two trials to evaluate the therapeutic potential of SONALA-001 SDT for DIPG and rGBM. The DIPG trial is actively recruiting and the rGBM clinical trial will begin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom